SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0648+8.0%Nov 11 3:24 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jm2i123 who wrote (12531)11/28/2013 12:04:55 PM
From: Jack Russell1 Recommendation

Recommended By
Khris Smith

  Read Replies (1) of 13111
 
Great article appearing in CancerWatch, Vol. 22 Oct. 2013,
Pages 155-156 reports the confirmation of high clinical response rates and further evidence of systemic effects for intralesional PV-10 emerging from an updated analysis of Phase 2 clinical data.

pvct.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News